Companies · Other Health Care

Posit Science Corp

SAN FRANCISCO · Other Health Care

Diligence memoA one-page analyst read on Posit Science Corp — recommendation, valuation, rhythm, risks.
$15.4M
Total raised · real
7
Rounds
2.1×
Latest step-up
Top 20%
Sector rank · raised
Series A
Latest stage · inferred · Tue Mar 29 2011 00:00:00 GMT+0000 (Coordinated Universal Time)

Posit Science Corp looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.17× the median modeled value of Series A Other Health Care companies in 2010–2012 (199 peers) — value vs value, same stage and era.
Dormant
  • Last raise 15.3 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

Posit Science Corp is one of 5376 Other Health Care companies tracked from SAN FRANCISCO. By capital raised it ranks in the upper tier (ahead of 81% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeries A · 2009-04-10 Raised $5.6M (real) Modeled valuation $112M (est)Series A2009Series A · 2009-05-01 Raised $296K (real) Modeled valuation $6.0M (est)Series A2009Series A · 2009-11-10 Raised $500K (real) Modeled valuation $10M (est)Series A2009Series A · 2009-12-23 Raised $2.4M (real) Modeled valuation $48M (est)Series A2009Series A · 2009-12-23 Raised $5.2M (real) Modeled valuation $106M (est)Series A2009Series A · 2010-09-22 Raised $455K (real) Modeled valuation $9.2M (est)Series A2010Series A · 2011-03-29 Raised $955K (real) Modeled valuation $19M (est)Series A2011+$296K+$500K+$2.4M+$5.2M+$455K+$955KCumulative $15M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$5.6M · 2009
Series A extension$296K · 2009
Series A extension$500K · 2009
Series A extension$2.4M · 2009
Series A extension$5.2M · 2009
Series A extension$455K · 2010
Series A extension$955K · 2011

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$19.3M
Base estimate est.
$1.2M
Conservative case
$104.8M
Upside case
$4.3M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Series A · modeled $112.3M · 2009-04-102009Series A · modeled $6.0M · 2009-05-01Series A · modeled $10.1M · 2009-11-10Series A · modeled $48.5M · 2009-12-23Series A · modeled $105.6M · 2009-12-23Series A · modeled $9.2M · 2010-09-22Series A · modeled $19.3M · 2011-03-292011
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
52%
Survival probability
28% low · 71% high
1.43×/yr
Annual markup
1.80×/yr upside case
6.0 yr
Elapsed time used
15.3 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
4 mo
Avg between rounds
$7.8M/yr
Capital velocity
17.2 yr
On record since
2009
First round
7
Rounds on file
How it compares to the market

Benchmarked against 5376 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 6.3× above median
This company$15.4M
Sector median$2.4M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.2× of median
This company$955K
Sector median$5.6M
Modeled value — vs sector median (estimate, all stages) 0.9× of median
This company$19.3M
Sector median$22.1M

Raised more than 81% of sector peers (real $). Modeled value above 47% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #178 of 199.

This companyCohort peer
$10.0M$100.0M$1.0B$10.0M$100.0MCapital raised (log)Barrx Medical Inc · Series A Raised $15.0M · modeled $302.7M (est)Cas Medical Systems Inc · Series A Raised $16.9M · modeled $302.7M (est)Icad Inc · Series A Raised $27.1M · modeled $302.7M (est)Cardiosolutions Inc · Series A Raised $18.5M · modeled $300.3M (est)Ophthonix Inc · Series A Raised $24.7M · modeled $283.4M (est)FMS Watertown, LLC · Series A Raised $13.7M · modeled $277.2M (est)Flowood Vascular Access, LLC · Series A Raised $13.7M · modeled $277.2M (est)Cardiovascular Systems Inc · Series A Raised $58.5M · modeled $272.4M (est)HemaSource Holdings LLC · Series A Raised $13.5M · modeled $272.2M (est)OMNI Home Health Acquisition, LLC · Series A Raised $12.6M · modeled $253.2M (est)Integrated Sleep Holdings Inc · Series A Raised $12.4M · modeled $249.9M (est)AngioScore Inc. · Series A Raised $12.0M · modeled $242.2M (est)Posit Science Corp (this company) Raised $15.4M · modeled $19.3M (est)Posit Science Corp
CompanyStageRaised · realValue · estvs peer med.
Barrx Medical IncSeries A$15.0M$302.7M2.60×
Cas Medical Systems IncSeries A$16.9M$302.7M2.60×
Icad IncSeries A$27.1M$302.7M2.60×
Cardiosolutions IncSeries A$18.5M$300.3M2.58×
Ophthonix IncSeries A$24.7M$283.4M2.44×
FMS Watertown, LLCSeries A$13.7M$277.2M2.38×
Flowood Vascular Access, LLCSeries A$13.7M$277.2M2.38×
Cardiovascular Systems IncSeries A$58.5M$272.4M2.34×
HemaSource Holdings LLCSeries A$13.5M$272.2M2.34×
OMNI Home Health Acquisition, LLCSeries A$12.6M$253.2M2.18×
Integrated Sleep Holdings IncSeries A$12.4M$249.9M2.15×
AngioScore Inc.Series A$12.0M$242.2M2.08×
Posit Science Corp this companySeries A$15.4M$19.3M0.17×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$5.6M2009-04-10$25.3M$112.3M90%
Series A$296K2009-05-01$1.3M$6.0M90%
Series A$500K2009-11-10$2.3M$10.1M90%
Series A$2.4M2009-12-23$10.9M$48.5M90%
Series A$5.2M2009-12-23$23.8M$105.6M90%
Series A$455K2010-09-22$2.1M$9.2M90%
Series A$955K2011-03-29$4.3M$19.3M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$5.6M2009-04-10
    • First recorded raise — entered as Series A.
  2. Series A$296K2009-05-01
    • Came back fast: 1 mo vs the ~14 mo sector norm.
    • Round 18.8× smaller than the prior — bridge or down round.
  3. Series A$500K2009-11-10
    • Came back fast: 6 mo vs the ~14 mo sector norm.
    • Round 1.7× larger than the prior — scaling up.
  4. Series A$2.4M2009-12-23
    • Came back fast: 1 mo vs the ~14 mo sector norm.
    • Round 4.8× larger than the prior — scaling up.
  5. Series A$5.2M2009-12-23
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.2× larger than the prior — scaling up.
  6. Series A$455K2010-09-22
    • Raised 9 mo later, in step with the ~14 mo sector norm.
    • Round 11.5× smaller than the prior — bridge or down round.
  7. Series A$955K2011-03-29
    • Came back fast: 6 mo vs the ~14 mo sector norm.
    • Round 2.1× larger than the prior — scaling up.
Intelligence
2011 ~Q3
Modeled next raise · ~4mo cadence
$2.0M
Modeled next size est.range $1.3M$3.2M
2.1×
Last step-up
$7.8M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
JOANNA REES6 other2009-12
Paul Klingenstein5 other2009-12
Vincent Kim3 other2011-03
Henry Mahncke2011-03
Horace B. Deets2010-09
Horace Deets2009-12
Jeffrey Zimman2009-05
Joanna B. Rees2010-09
Jonathan Zimman2009-05
Michael Merzenich2009-05
Steven Aldrich2009-04
Vincent B. Kim2010-09
Registry & provenance

Posit Science Corp is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1327529
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Cervel Neurotech, Inc.Other Health CareSeries A$37.2M$20.2Mnetwork1 shared operator · same sector · same stage
Akadeum Life Sciences, Inc.Other Health CareSeries A$15.4M$20.5Msame sector · same stage
Better Management Holdings, LLCOther Health CareSeries A$15.0M$22.8Msame sector · same stage
Fusion Orthopedics USA, LLCOther Health CareSeries A$15.0M$18.3Msame sector · same stage
83Bar, Inc.Other Health CareSeries A$14.6M$22.4Msame sector · same stage
Cellceuticals Skin Care IncOther Health CareSeries A$14.4M$21.5Msame sector · same stage
Structural Elements Holdings, LLCOther Health CareSeries A$14.4M$19.1Msame sector · same stage
Integrity Implants Inc.Other Health CareSeries A$13.6M$21.2Msame sector · same stage
Frequently asked
How much funding has Posit Science Corp raised?
Posit Science Corp has raised approximately $15.4M in disclosed capital across 7 recorded financing rounds, aggregated from public filings.
What is Posit Science Corp's estimated valuation?
Provath's modeled valuation for Posit Science Corp is approximately $19.3M (modeled range $1.2M–$104.8M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Posit Science Corp at?
Posit Science Corp's latest modeled financing stage is Series A. Its most recent recorded round closed around Tue Mar 29.
What does Posit Science Corp do and where is it based?
Posit Science Corp operates in the Other Health Care sector, based in SAN FRANCISCO.
Explore related

See where Posit Science Corp sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Posit Science Corp, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.